ReviewPostepy w kardiologii interwencyjnej = Advances in interventional cardiology2025
The effect of nicorandil compared to placebo on cardiac outcomes of patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis.
Review in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nicorandil (2-nicotinamidoethyl-nitrate ester) is an ATP-sensitive potassium channel opener with the ability to donate nitric oxide (NO), which can increase coronary blood flow, particularly at the microcirculation level. Recent clinical trials have reported that nicorandil treatment during percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) patients can modulate their clinical outcomes; however, its effects on STEMI patients vary widely across different studies and patient subgroups. Methods: PubMed, Web of Science, Scopus, and Cochrane Library were systematically searched from inception to October 6, 2024. Due to significant heterogeneity, a random-effects model was adopted to pool data. Results: In this study, a total of 1802 participants in the control group and 1844 participants in the nicorandil group were included. Nicorandil treatment during PCI significantly decreased arrhythmia (RR = 0.52, 95% CI [0.32, 0.84], Conclusions: Intracoronary nicorandil treatment during PCI in STEMI patients can significantly impact several important clinical outcomes, such as arrhythmia, coronary blood flow rate, and re-hospitalization incidence, but does not show significant effects on chest pain, cardiovascular death, and heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.